On September 30, 2015, an Illinois federal judge decided in favor of Finnegan client Cumberland Pharmaceuticals, ruling that Mylan Institutional LLC infringed Cumberland's patent for the drug Acetadote. In 2012, Cumberland filed a complaint claiming that Mylan infringed its patent by filing an abbreviated new drug application (ANDA) with the FDA in an effort to obtain approval to market a generic version of the drug. In district court, Mylan claimed that the formulation was derived from the U.S. Food and Drug Administration (FDA) and was not Cumberland's invention, but the court held that the FDA's formula for Acetadote was not a "definite and permanent" idea.
Award/Ranking
Managing IP Americas Awards 2024: Finnegan Shortlisted for Nine Awards, Including Firm of the Year
March 12, 2024
Commentary
February 29, 2024
Press Release
Finnegan Secures Another Patent Victory for BMW Group in the District of Delaware
February 27, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.